Expert consensus on clinical application of Wangbi Tablets in treating rheumatoid arthritis and knee osteoarthritis.
10.19540/j.cnki.cjcmm.20210125.501
- Author:
Wei-Heng CHEN
1
;
Xi-Sheng WENG
2
;
Xiao-Ping YAN
3
;
Wei LIU
4
;
Ying-Hui JIN
5
;
Na LIN
6
;
Yan ZHAO
7
Author Information
1. Third Affiliated Hospital, Beijing University of Chinese Medicine Beijing 100029, China.
2. Peking Union Medical College Hospital Beijing 100730, China.
3. China-Japan Friendship Hospital Beijing 100029, China.
4. First Teaching Hospital of Tianjin University of Traditional Chinese Medicine Tianjin 300193, China.
5. Center for Evidence-based and Translational Medicine of Wuhan University Wuhan 430071, China.
6. Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences Beijing 100700, China.
7. Wangjing Hospital, China Academy of Chinese Medical Sciences Beijing 100102, China.
- Publication Type:Journal Article
- Keywords:
Wangbi Tablets;
expert consensus;
knee osteoarthritis;
rheumatoid arthritis
- MeSH:
Arthritis, Rheumatoid/drug therapy*;
Consensus;
Drugs, Chinese Herbal;
Humans;
Medicine, Chinese Traditional;
Osteoarthritis, Knee/drug therapy*;
Tablets
- From:
China Journal of Chinese Materia Medica
2021;46(17):4569-4574
- CountryChina
- Language:Chinese
-
Abstract:
Wangbi Tablets are widely used in the treatment of rheumatoid arthritis, knee osteoarthritis and other diseases at pre-sent. Long-term clinical application and research have shown that this drug has a good effect in reducing the pain of related diseases and improving symptoms. Due to the lack of guidance in the instructions and currently no relevant norms to guide the clinical application of Wangbi Tablets, in order to further improve clinicians' understanding of the drug and fully tap the clinical advantages of the drug, the Professional Committee of Orthopedics and Traumatology Drug Research of China Association of Chinese Medicine organized experts in the fields of rheumatism, orthopedics, pharmacy and methodology in Chinese and western medicine to develop expert consensus on Chinese patent medicines in accordance with the relevant requirements of the consensus methodology. Based on full consideration of clinical research evidence and expert experience, the clinical issues were summarized in the consensus, and for those clinical problems supported by evidences, the internationally recognized recommendation evaluation and formulation method GRADE was used to evaluate the evidence and form recommendations; for those clinical issues not supported by evidences, a consensus was reached through the nominal group method to form consensus recommendations. The consensus adopted a concise and clear format to form re-commendations or reach consensus suggestions on the medication regimen, medication characteristics, intervention timing, usage and dosage, course of use and safety issues for the treatment of rheumatoid arthritis and knee osteoarthritis with Wangbi Tablets. It is suggested that its application will better improve the efficacy of Wangbi Tablets in the treatment of rheumatoid arthritis and knee osteoarthritis, at the same time provide a reference for clinicians to use Wangbi Tablets in a standardized, reasonable and safe manner.
